Fibrolamellar Hepatocellular Carcinoma : What Younger Patients Need to Know скачать в хорошем качестве

Fibrolamellar Hepatocellular Carcinoma : What Younger Patients Need to Know

Fibrolamellar Hepatocellular Carcinoma (FL-HCC) is a rare and biologically distinct type of primary liver cancer that predominantly affects adolescents and young adults, often between the ages of 15 and 40. Unlike conventional hepatocellular carcinoma, which usually develops in the setting of chronic liver disease such as cirrhosis or viral hepatitis, fibrolamellar carcinoma arises in individuals with previously healthy livers. This unexpected presentation can delay diagnosis, as neither patients nor healthcare providers may initially suspect a serious liver condition. The rarity of the disease and its occurrence in younger populations make awareness and accurate understanding especially important. One of the defining features of fibrolamellar hepatocellular carcinoma is its unique cellular structure. The tumor is composed of large cancer cells separated by dense fibrous bands, which gives the disease its name and distinguishes it from other liver cancers under microscopic examination. In many cases, FL-HCC is associated with a specific genetic alteration known as the DNAJB1-PRKACA fusion, a finding that has helped advance diagnostic accuracy and ongoing research efforts. Despite these identifiable features, the disease often grows silently, as liver function typically remains preserved during early stages. Symptoms of fibrolamellar hepatocellular carcinoma are often vague and nonspecific, which contributes to delayed detection. Patients may experience persistent abdominal pain or pressure, unexplained weight loss, fatigue, nausea, reduced appetite, or a sensation of fullness caused by an enlarging liver mass. Because jaundice and signs of liver failure are less common early on, tumors are frequently diagnosed at a larger size or after spreading beyond the liver. Accurate diagnosis generally requires a combination of advanced imaging techniques, tissue biopsy, and specialized pathological and genetic evaluation. Treatment for fibrolamellar hepatocellular carcinoma differs from that of more common liver cancers. Surgical removal of the tumor is the primary and most effective treatment when the disease is localized, and many patients are candidates for surgery due to otherwise healthy liver tissue. In selected cases, liver transplantation, systemic therapies, or clinical trial participation may be considered, particularly when the cancer has advanced or recurred. Prognosis varies depending on stage, surgical outcomes, and tumor behavior, but long-term survival is possible, especially with specialized care. Ongoing research continues to focus on targeted therapies and improved management strategies to enhance outcomes for younger patients affected by this rare liver cancer.